Results 91 to 100 of about 9,765 (234)

Recent Advancements in Known and Emerging Risk Factors of Hepatocellular Carcinoma

Cancer Medicine, Volume 14, Issue 21, November 2025.
ABSTRACT Background Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and a leading cause of cancer‐related deaths worldwide. Despite advancements in antiviral therapies for hepatitis B (HBV) and hepatitis C (HCV), HCC incidence continues to rise due to metabolic dysfunction‐associated steatotic liver disease (MASLD), obesity ...
Muhammad Masroor Hussain, Bi Feng, Ju‐Mei Wang, Ao‐Qiang Zhai, Fu‐yu Li, Hai‐jie Hu   +5 more
wiley   +1 more source

Small Molecule Targeting of Atypical p38 Protects Against Viral Infection

The FASEB Journal, Volume 39, Issue 20, 31 October 2025.
Targeting host signaling pathways offers a complementary strategy to direct‐acting antivirals. Small‐molecule modulators of atypical p38 block Hepatitis C virus replication and also inhibit Human Cytomegalovirus. By disrupting virus‐induced p38 activation, these compounds suppress viral RNA replication and protein expression, highlighting atypical p38 ...
Fredejah T. Royer, Jeremy C. Burton, Johnathan Burns, Megan G. Lloyd, Reuben Onwe, Jennifer F. Moffat, Neil J. Grimsey   +6 more
wiley   +1 more source

Minimum target prices for production of direct acting antivirals and associated diagnostics to combat Hepatitis C Virus [PDF]

, 2014
Combinations of direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naïve patients. Mass treatment programs to cure HCV in developing countries are only feasible if the costs of treatment and laboratory ...
Cooke, GS, Ford, N, Fortunak, J, Hill, A, Khoo, S, Simmons, B, van der Ven, N   +6 more
core   +2 more sources

From Guidelines to Real‐Time Conversation: Expert‐Validated Retrieval‐Augmented and Fine‐Tuned GPT‐4 for Hepatitis C Management

Liver International, Volume 45, Issue 10, October 2025.
ABSTRACT Background and Aims Advances in artificial intelligence, particularly large language models (LLMs), hold promise for transforming chronic disease management such as Hepatitis C Virus (HCV) infection. This study evaluates the impact of retrieval‐augmented generation (RAG) and supervised fine‐tuning (SFT) on both open‐ended question answering ...
Mauro Giuffrè, Nicola Pugliese, Simone Kresevic, Milos Ajcevic, Francesco Negro, Massimo Puoti, Xavier Forns, Jean‐Michel Pawlotsky, Dennis L. Shung, Alessio Aghemo   +9 more
wiley   +1 more source

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection

Annals of Hepatology, 2016
Background. Patient race and ethnicity have historically impacted HCV treatment response. This phase 3 study evaluated daclatasvir with peginterferon-alfa-2a/ribavirin (pegIFN alfa-2a/RBV) in treatment-naive black/African American (AA), Latino, and white
Maribel Rodriguez-Torres, Eric Läwitz, Bienvenido Yangco, Lennox Jeffers, Steven-Huy Han, Paul J. Thuluvath, Vinod Rustgi, Stephen Harrison, Reem Ghalib, John M. Vierling, Velimir Luketic, Philippe J. Zamor, Natarajan Ravendhran, Timothy R. Morgan, Brian Pearlman, Christopher O’Brien, Hicham Khallafi, Nikolaos Pyrsopoulos, George Kong, Fiona McPhee, Philip D. Yin, Eric Hughes, Michelle Treitel   +22 more
doaj   +1 more source

Viral hijacking of cellular metabolism. [PDF]

, 2019
This review discusses the current state of the viral metabolism field and gaps in knowledge that will be important for future studies to investigate.
Ch'ng, James, Christofk, Heather R, Thaker, Shivani K   +2 more
core  

NSP7 Molecular Degrader Attenuates Coronaviral Infection Through the β‐TrCP1/FBXO5 Axis

Advanced Science, Volume 12, Issue 36, September 25, 2025.
Host E3 ligase FBXO5 as a key regulator that promotes K48‐linked ubiquitination and proteasomal degradation of SARS‐CoV‐2 NSP7, thereby suppressing viral replication. NSP7 ubiquitination is co‐regulated by β‐TrCP1 and TAF1. Small molecule BC24877 disrupts β‐TrCP1‐mediated degradation of FBXO5, stabilizing FBXO5 and enhancing NSP7 clearance ...
Yao Tong, Travis B. Lear, Ferhan Tuncer, John J. Villandre, Áine N. Boudreau, Bo Lin, Irene Alfaras, Jason R. Kennerdell, Daniel P. Camarco, Mads B. Larsen, Yun Hua, Yanwen Chen, Meigin E. Chandler, Ricardo Pineda, Simon M. Barratt‐Boyes, John W. Evankovich, Toren Finkel, Yuan Liu, Bill B. Chen   +18 more
wiley   +1 more source

Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies [PDF]

, 2018
[Abstract] The presence of resistance‐associated substitutions (RASs) at NS5A region might compromise the efficacy of Direct Acting Antiviral agents (DAAs).
Bagaglio, Black, Calleja, Chen, Dietz, Foster, Kalaghatgi, Lindström, Nelson, Palladino, Paolucci, Pawlotsky, Plaza, Poveda, Poveda, Pérez, Sarrazin, Wyles, Zeuzem, Zeuzem, Zeuzem   +20 more
core   +2 more sources

Study on Antibacterial Activity of Water Extract of Galla chinensis Against Carbapenemase‐Producing Enterobacteriaceae

MicrobiologyOpen, Volume 14, Issue 4, August 2025.
Galla chinensis is an eco‐friendly and effective alternative to traditional antibiotics for combating multidrug resistance. ABSTRACT Carbapenemase‐producing Enterobacteriaceae (CPE) represents a significant global public health concern, largely driven by factors including misuse of antibiotics and their inappropriate use in livestock.
MinHui Miao, Jiayao Lin, Jie Zhu, Hong Du, Di Mei, AnQi Gu, BeiNa Hu, HaiQiang Jiang   +7 more
wiley   +1 more source

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals [PDF]

, 2017
In recent years, great progress has been made in the field of new therapeutic options for hepatitis C virus (HCV) infection. The new direct-acting antiviral agents (DAAs) represent a great hope for millions of chronically infected individuals because ...
Caputo, Mariela, Corach, Daniel, Flichman, Diego Martin, Hulaniuk, María L., Trinks, Julieta   +4 more
core   +1 more source